HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Archives for Featured

A Conversation With Ge Bai Regarding Amazon’s Pharmacy Foray

In a recent podcast with Dr. Ge Bai of Johns Hopkins, important points are discussed relating to Amazon’s venture into the pharmacy space. Her extensive background in in public health and business make for an informative discussion. She discusses PBMs (pharmacy benefit managers) and the reasons […]

more info 02/22/2021View Related Articles
Bookmark and Share

Do Hospitals Actually Mark Up Medications 250%?

A recent report examines the cost differences regarding medications in hospitals. A comparison across two dozen drugs led to the finding that the markup is an average of 250%. Over 30% of the hospitals included in the analysis did not stock biosimilars for the drugs analyzed. Although insurance […]

more info 02/22/2021View Related Articles
Bookmark and Share

HealthEconomics.Com’s Value and Evidence Marketplace Seeking Organizations With EHR Data

The Value and Evidence Marketplace is an online tool that matches biomedical and biopharmaceutical researchers with suppliers for research. 24 of the top 30 pharmaceutical companies, along with over 75 biotech companies, utilize our Marketplaces in their studies. Clients are increasingly interested […]

more info 02/22/2021View Related Articles
Bookmark and Share

Report on Impact of COVID-19 on Global Bioinformatics Market

A recent report discusses how COVID-19 affected the Bioinformatics Market. The impacts on five currencies (USD, EUR, AUD, GBP, JPY) are discussed. Chemoinformatics, genomics, proteomics, metabolomics, and transcriptomics were discussed, among other categories. The report addressed market […]

more info 02/19/2021View Related Articles
Bookmark and Share

Prediction Models for COVID-19 Can’t Account for All Human Elements

Early in the COVID-19 pandemic, researchers were scrambling to predict how the disease would spread. One such model was developed at the University of Illinois, Urbana-Champaign, by two physicists: Nigel Goldenfeld and Sergei Maslov. They were able to adapt some of the tools used in their physics […]

more info 02/19/2021View Related Articles
Bookmark and Share

Amalgam Rx, Inc. Acquires Avhana Health

Amalgam Rx. Inc. has acquired Avhana Health, a clinical decision support company with experience in electronic health records. This move will allow Amalgam Rx to build on Avhana’s existing tools and to expand into additional therapeutic areas. The result will be a simplified workflow for […]

more info 02/19/2021View Related Articles
Bookmark and Share

Meta-Analysis Study on Kidney Cancer Utilizes Novel Techniques to Identify Biomarkers

The survival rates of patients with kidney cancer largely depend on identifying biomarkers. The identification of these biomarkers can help determine a course of treatment. A recent study, published in JAMA, compares data from 6 clinical trials and reported in 9 publications. The report examined how […]

more info 02/19/2021View Related Articles
Bookmark and Share

Caesarean Section Procedure Can Vary in Price From 6k to 60k—At the Same Hospital

Women who undergo a caesarean section at the Van Ness site of the Pacific Medical Center in California might be surprised to find that the cost of their procedure may be vastly different from that of another woman in the same hospital. Costs range from $6,241 to $60,584 for this particular […]

more info 02/19/2021View Related Articles
Bookmark and Share

Webinar: Reflections on Healthcare in 2020 and Visions for 2021

In a recent webinar, the authors discuss important changes and developments in 2020 regarding healthcare regulations. The fast pace of change is expected to continue through 2021. The No Surprises Act passed in December 2020, meant to address unexpected medical bills, will bring changes to a diverse […]

more info 02/18/2021View Related Articles
Bookmark and Share

Webinar on RWE and Progress During COVID-19 Pandemic

The COVID-19 Pandemic has driven many researchers to incorporate RWE (real world evidence) into clinical trials. However, it can often be challenging to accomplish this task. In this webinar, Sandy Leonard and Akiko Shimamura of HealthVerity discuss advances regarding RWE in clinical trials. “The […]

more info 02/18/2021View Related Articles
Bookmark and Share

Using Bayesian Methods in Control Arms of Clinical Trials

The use of single arm trials has become more widespread, especially as the COVID-19 has forced clinical trials to change or end early. An alternative approach is the use of synthetic control arms (SCAs), arms that can be created using Bayesian Dynamic Borrowing. In this method, data from patients […]

more info 02/18/2021View Related Articles
Bookmark and Share

New Report Details How SDOH Impact Access to Prescription Drugs

In a recent report, CoverMyMeds discusses how SDOH (social determinants of health) are associated with many patients being forced to make difficult choices when it comes to their health. The COVID-19 pandemic has made these choices even more challenging as more Americans become uninsured or […]

more info 02/18/2021View Related Articles
Bookmark and Share

6 Recommendations Regarding HTAs in the United States

A whitepaper was recently released by researchers at the USC Schaeffer Center and the Aspen Institute. The authors discuss half a dozen recommendations relating to HTAs (Health Technology Assessments) in the United States, which could lead to changes in the pricing of prescription drugs. […]

more info 02/18/2021View Related Articles
Bookmark and Share

A Conversation with Peter Pitts on Drug Pricing and Medicare

In a recent podcast by Patients Rising Podcast, the hosts spoke with Peter Pitts. He co-founded and is currently president of the Center for Medicine in the Public Interest. He’s also served as Associate Commissioner for External Relations for the FDA, written a book on successful leadership, and […]

more info 02/17/2021View Related Articles
Bookmark and Share

Outcry Over Nick Jonas in Super Bowl Commercial for Dexcom

Type 1 Diabetics typically check their blood glucose levels by pricking their finger with a needle to obtain a small blood sample. Insulin injections regulate this blood glucose level, but can cause significant financial hardship. In a Super Bowl commercial for Dexcom, Nick Jonas promoted an […]

more info 02/17/2021View Related Articles
Bookmark and Share

Will a Committee Lead to Reduced Drug Prices in the United States?

Will a Committee Lead to Reduced Drug Prices in the United States The idea of an independent review board to regulate drug prices is gaining ground. Although pharmaceutical companies protest such a committee, pointing at lost innovation, many in the US support a Health Technology Assessment (HTA) […]

more info 02/17/2021View Related Articles
Bookmark and Share

New PhRMA Report Details Role of Hospitals in High Drug Costs

A recent PhRMA discusses how hospitals contribute to the high prices of drugs in the United States. Typically, pharmaceutical companies, insurance companies, and patients are discussed in the context of high prices, not hospitals. However, depending on whether or not patients receive medication from […]

more info 02/17/2021View Related Articles
Bookmark and Share

Insight Regarding RWE, RWD and COVID-19

In a recent conversation with Jeff Elton, CEO of ConcertAI, he discussed changes to the pharmeceutical industry resulting from the COVID-19 pandemic. Both RWE (real world evidence) and RWD (real world data) provide remarkable insight regarding patient care and outcomes. RWE provides a possible […]

more info 02/17/2021View Related Articles
Bookmark and Share

Do COVID-19 Vaccine Manufacturers Worry Over Pricing Language in Contracts?

Despite objections by pharmaceutical companies against price regulations, at least three major companies agreed to such terms in the context of COVID-19 vaccine contracts. Although the COVID-19 constitutes an unexpected situation, these contracts set a precedent for future agreements regarding price […]

more info 02/16/2021View Related Articles
Bookmark and Share

How Will the United States Address High Drug Prices?

American legislators are frustrated by high drug prices. In addition to financial distress from medication payments, some patients resort to modifying their medication dosages. Now, both Democrats and Republican around the country are sponsoring bills to limit these drug prices, rather than waiting […]

more info 02/16/2021View Related Articles
Bookmark and Share

CPE Webinar on COVID-19 Treatments and Vaccines

A webinar will take place on Thursday, February 25th from 2-3 PM ET. This free webinar will cover newly developed therapies to treat patients with COVID-19, as well as adapting previously developed drugs to COVID-19. Vaccine distribution will also be discussed. “This session will review the most […]

more info 02/16/2021View Related Articles
Bookmark and Share

Case Study Shows Power of RWE

A new case study from Cardinal Health highlights the value of RWE (real world evidence) in clinical trials. This RWE data helped a biopharmaceutical company speed up the FDA approval process for their product. “See how experts from our Real-World Evidence and Insights team helped a […]

more info 02/16/2021View Related Articles
Bookmark and Share

Changes for BresMed and Cello

In 2020, private equity firm Arsenal Capital Partners acquired BresMed and Cello, two independent biopharma companies. Now, BresMed and Cello will combine to offer unique solutions to their clients. These companies have experience in health economic and outcomes research and in advising global […]

more info 02/16/2021View Related Articles
Bookmark and Share

The Positive Impact of COVID-19 on Clinical Trials

Although COVID-19 has resulted in many negative consequences, it has also brought about some useful changes in the drug development and clinical trial space. Patients who faced barriers to clinical trial enrollment have been able to participate—especially in instances where remote data is collected, […]

more info 02/15/2021View Related Articles
Bookmark and Share

New Report Improves Health of Market Access Teams

The success of a product requires many resources and a dedicated team. It also requires contingency plans if one small piece fails. A new eBook details how you and your team can be successful in areas relating to patient support and managing data. “Just as patients are encouraged to get annual […]

more info 02/15/2021View Related Articles
Bookmark and Share

Growing Support for HTA in Light of High Gene Therapy Costs

An independent review board, such as ICER, responsible for assessing appropriate costs for therapies and drugs has been discussed for years. Calls for such a health technology assessment board (HTA) are increasing as many note that novel cell and gene-based therapies, while many times effective, are […]

more info 02/15/2021View Related Articles
Bookmark and Share

ICER Releases Draft Evidence Report for Several Multiple Myeloma Therapies: Will These Drugs Prevent Relapse?

ICER has released a report on three therapies for multiple myeloma: belantamab mafodotin blmf from Blenrep™ and GlaxoSmithKline, idecabtagene vicleucel from Bristol-Myers Squibb and bluebird bio, and ciltacabtagene autoleucel from Janssen and Legend biotech. Belantamab mafodotin blmf is an antibody […]

more info 02/15/2021View Related Articles
Bookmark and Share

COVID-19 News: Eli Lilly Drug Receives FDA Emergency Authorization; Drug Pricing Language in COVID-19 Bill

Two recent developments related to COVID-19 are a new drug approval and a relief bill containing a drug pricing proposal. A combination therapy of two antibodies from Eli Lilly has been shown to be effective in reducing hospitalization and death rates from COVID-19. These two drugs (bamlanivimab and […]

more info 02/15/2021View Related Articles
Bookmark and Share

Value Communications in 2021: Where can we improve?

HealthEconomics.Com is seeking at least 300 global respondents our 2021 Value Communications survey. Developing, assessing and communicating the value of pharmaceuticals and medical devices is essential, but there are few training programs or standards. The 2021 Value Communications survey objective […]

more info 02/15/2021View Related Articles
Bookmark and Share

A $10 Drug Price Increase Is Correlated with Higher Mortality Rate of 33%

A new study reveals that even a small increase in prescription drug prices—of only $10—can lead to higher mortality rates. They note that a price increase of 34%, equivalent to $10.40, was associated with a 33% increase in mortality rate. The article explores possible solutions to reducing this cost […]

more info 02/12/2021View Related Articles
Bookmark and Share

  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 121
  • Next Page

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Aetion’s new eBook – The role of real-world evidence in FDA approvals
  • Cytel Scientists Call for a “Statistician-First Workflow” to Optimize Drug Development
  • Specialty Pharmacy Virtual Technology Adoption on the Rise
  • Clinical Trials Have Changed. Has Your Tech Strategy?
  • Beyond COVID-19: Life sciences reimagined
  • How Real-World Evidence Can Support Adoption of New Technology
  • Interventional Studies
  • Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic
  • Pediatric Drug Development: Trends and Perspectives in the United States
  • Can Clinical Studies Go Virtual?
  • ICER’s impact on payer decision making
  • Representation and Diversity in Clinical Trials
  • Advisory Boards: The Good, The Bad, and The Ugly
  • An Initial Framework to Describe and Classify Integrated Scientific Advice Procedures
  • Ensuring timely dissemination of research: a guide to working as a medical publications professional
  • Patient Intelligence and Insights Reports
  • Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines
  • Patient Centricity
       Exploring the patient dynamic from different perspectives
  • How to Excel at Next Generation Trial Execution
  • Payers: The New Catalysts of Better Health
  • A writer’s role in drug development: a guide to getting started in regulatory medical writing
  • Virtual Medical Conferences: The new normal?
  • How Healthy Are Your Market Access Programs? ​​​​​​​A guide to performing check-ups on pharmaceutical distribution and patient access programs
  • The Overlooked Patient: How payers can identify, engage and treat the vulnerable populations not participating in their own care
  • Unlocking the potential of a Chief Outcomes Officer
  • Pharma’s path for digital health solutions
  • Gartner 2020 Magic Quadrant for Data Science + Machine Learning Platforms
  • How Are Changing Reimbursement Models Affecting Denials?
  • Regulation and Market Climate Force the Issue of CDM Prices
  • The Missing C-Suite Role

Syndicated Reports

  • Medical Affairs: The Roadmap to 2025
  • Health Economics & Outcomes Research (HEOR) Services Market Share & Forecast, 2020–2026
  • Pharmaceutical Payment System Market – Quantitative Analysis, Current and Future Trends, 2020 – 2027
  • The Future of Personalised Medicine: The Role of Simulation and Digital Twins
  • Medical Diagnostics: leveraging new opportunities from AI driven technology
  • Massive Growth in Digital Health Technology Market by Athenahealth, McKesson Corporation, Qualcomm, LifeWatch, AT & T, Cerner Corporation, Philips Healthcare, Cisco Systems
  • Real World Evidence: The Role of Medical Affairs
  • Pharmacy Benefit Management (PBM) – Industry Size 2019, Market Opportunities, Share Analysis up to 2025
  • Democrats and Drug Pricing
  • Global Health Economics & Outcomes Research (HEOR) Services Market Size, Share, Growth, Status and Forecast 2019-2025
  • Global Value-Based Reimbursement Software Market Size, Status and Forecast to 2026
  • Benchmarking Key Account Management Capabilities (2019)
  • The Future of Key Account Management in Pharma
  • Indication-level Pricing: Payer Insights
  • Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
  • Success in Managed Markets: Payer Insights
  • Real World Data and Evidence: Payer Insights
  • KAM Metrics: Measuring Success (2019)
  • Biomarkers and Companion diagnostics: Payer Insights
  • Paying for Digital Health: Payer Insights (2019)
  • Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026
  • Biosimilars: US Payer Insights (2019)
  • Review of Influence: The Institute for Clinical and Economic Review
  • Innovative Drugs: Mapping the Pricing and Reimbursement Landscape
  • Orphan Drugs: European Payer Perspectives
  • Do Payers Really Want Pay-for-Performance?
  • Payer Engagement: Benchmarking Team Structure and Activity
  • Benchmarking Market Access Strategies for High-Cost Drugs and Biologics
  • Blockchain: Transformational Change for Pharma?
  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • HealthEconomics.Com Recognized as Top Influencer at ISPOR International Meeting in Washington DC
  • Will ICER Framework Destroy Progress Against Multiple Myeloma?
  • Celgene Unleashes the Power of Data into Clinical Trial Design
  • How Well is Harvoni Working in the Real World?
  • New CVS and Express Scripts Value Based Plans for Oncology
  • Oversized Cancer Drug Vials Waste $3B Each Year
  • Can More Data Make Providers’ Jobs Easier?
  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Take This Survey for a Chance to Win $200!
  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • ICER Releases Two Draft Reports on Obeticholic Acid
  • What do Patient Advocates Think of New ICER Report?
  • Could a New ICER Report Put Patients at Risk?
  • Contact Us

About

  • International Myeloma Foundation Responds to ICER Report
  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • Doctor Evidence Launches GROWTH Replicator Program
  • Is PCORI Underfunding CER?
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute